Amplification primer pairs, locked nucleic acid probes, kits and applications for detecting nucleic acids of atypical respiratory pathogens
By designing specific amplification primer pairs and nucleic acid lock probes, combined with real-time fluorescence quantitative PCR technology, the problem of difficult to detect multiple respiratory atypical pathogens at the same time in the prior art is solved, and the Bautista pertussis and pulmonary philtrum is achieved Rapid and accurate detection of Legionella, Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachoma improves the specificity and sensitivity of the detection.
Patent Information
- Application Number
- CN202210922296.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-02
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-08-02
AI Technical Summary
The prior art is difficult to detect multiple respiratory atypical pathogens at the same time, which leads to difficulty in diagnosis. In particular, the detection methods of Bautista pertussis, Legionella pneumoniae, Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachoma are cumbersome and have low sensitivity.
A specific amplification primer pair and locked nucleic acid probe were designed for these pathogens. Combined with real-time fluorescence quantitative PCR technology, the simultaneous detection of multiple pathogens is achieved through the multiple fluorescence quantitative PCR platform, and the specificity of detection is improved by using locked nucleic acid probes and Sensitivity.
It realizes rapid and accurate detection of a variety of atypical pathogens in the respiratory tract, improves the specificity, sensitivity and repetition of the detection, simplifies the experimental process, and is suitable for most real-time fluorescence quantitative PCR instruments.
Smart Images

Figure CN116121407B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biological detection technology, and in particular to an amplification primer pair, a locked nucleic acid probe, a kit and applications for detecting atypical respiratory pathogens. Background Art
[0002] Bordetella pertussis, commonly known as Bordetella pertussis, is a Gram-negative bacillus and the main pathogen of pertussis. Pertussis is a respiratory infectious disease with a high mortality rate in infants and young children. Legionella is also a Gram-negative bacillus that can cause systemic infection mainly in the lungs, collectively known as Legionnaires' disease, of which more than 85% is caused by Legionella pneumophila. Although Bordetella pertussis and Legionella pneumophila are both bacteria, they have strict nutritional requirements and are not easy to culture in vitro. Chlamydia is a prokaryotic cell-type microorganism that is an obligate intracellular parasite. The method of isolation and culture is cell culture and chicken embryo inoculation, so the operation is very cumbersome and difficult to achieve in clinical work. Among Chlamydia, Chlamydia pneumoniae and Chlamydia trachomatis can cause respiratory infections. Mycoplasma is the smallest prokaryotic cell-type microorganism, among which Mycoplasma pneumoniae is one of the common pathogens that cause human respiratory infections. Mycoplasma pneumoniae can be cultured in non-living culture medium, but the positive rate of isolation culture is not high, the culture sensitivity is only about 40%, and it is time-consuming, so it is not suitable for rapid clinical diagnosis.
[0003] Immunological methods are often used to detect pathogens that are difficult to culture. Although immunological methods have the advantages of strong specificity, high sensitivity, simple and fast operation, most of them can only detect one pathogen at a time, and most respiratory infections are co-infections with multiple pathogens. It is difficult to make a rapid differential diagnosis by conventional testing alone. The multiplex fluorescence quantitative PCR detection platform is the most mature open platform with relatively low construction and use costs. It is currently the focus of new reagent research and development. Concentrating the detection of multiple pathogens in a closed system and performing them simultaneously saves both cost and time, and has high sensitivity, greatly improving the detection rate of pathogens.
[0004] According to the registration information of the detection kits for the above five respiratory pathogens published on the website of the State Food and Drug Administration (https: / / www.nmpa.gov.cn / ), it is found that although the detection kits for these pathogens include PCR methods, the most common ones are still mainly based on various immunological methods; currently, among the kits for detecting the above pathogens using PCR, there are only two types of kits that can jointly detect two or more of the above pathogens, namely the Mycoplasma pneumoniae and Chlamydia pneumoniae nucleic acid combined detection kit, and the Chlamydia trachomatis, Chlamydia pneumoniae and Mycoplasma pneumoniae nucleic acid detection kits. See Table 1 for details.
[0005] Table 1 Methods of detection kits for the five atypical respiratory pathogens published by the State Food and Drug Administration
[0006]
[0007] Locked nucleic acids (LNA) are new nucleic acid analogs that contain a 2'-oxygen 4'-carbon methylene connection, which limits the flexibility of the furanose ring and locks its structure into a rigid double-ring pattern, which can improve hybridization efficiency and stability. LNA-labeled probes can enhance the thermal stability of the duplex. Each additional monomer LNA molecule will increase its melting point by 8°C. The optimal melting point (Tm) and hybridization specificity can be adjusted by adjusting the position of the LNA base in the probe. PCR probes containing LNA are shorter in length, which can increase the flexibility of primer and probe design. They are superior to the TaqMan-MGB method and can significantly expand the environmental limits of detection. At the same time, they allow more complex experiments to be performed in a single test tube, which is particularly suitable for multiplex real-time quantitative PCR systems. Summary of the invention
[0008] The purpose of the present invention is to provide an amplification primer pair, a locked nucleic acid probe, a kit and an application for detecting atypical respiratory pathogens, so as to solve the technical problem in the prior art that most tests can only detect one pathogen each time, while most respiratory infections are co-infections with multiple pathogens, and it is difficult to perform rapid differential diagnosis by conventional tests alone.
[0009] To achieve the above object, the present invention provides the following technical solutions:
[0010] The amplification primer pairs for detecting nucleic acids of atypical respiratory pathogens provided by the present invention include amplification primer pairs for Bordetella pertussis, Legionella pneumophila, Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachomatis;
[0011] The sequences of the amplification primer pair for Bordetella pertussis are shown in SEQ ID No. 1 and SEQ ID No. 2;
[0012] The sequences of the amplification primer pair for Legionella pneumophila are shown in SEQ ID No. 3 and SEQ ID No. 4;
[0013] The sequences of the amplification primer pair for Chlamydia pneumoniae are shown in SEQ ID No. 5 and SEQ ID No. 6;
[0014] The sequences of the amplification primer pair for Mycoplasma pneumoniae are shown in SEQ ID No. 7 and SEQ ID No. 8;
[0015] The sequences of the amplification primer pair for Chlamydia trachomatis are shown in SEQ ID No. 9 and SEQ ID No. 10.
[0016] Furthermore, the amplification primer pairs are divided into two groups, A and B: Group A includes amplification primer pairs for Bordetella pertussis and Legionella pneumophila; Group B includes amplification primer pairs for Chlamydia pneumoniae, amplification primer pairs for Mycoplasma pneumoniae, and amplification primer pairs for Chlamydia trachomatis.
[0017] The locked nucleic acid probes for detecting nucleic acids of atypical respiratory pathogens provided by the present invention include locked nucleic acid probes for Bordetella pertussis, Legionella pneumophila, Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachomatis;
[0018] The sequence of the locked nucleic acid probe for Bordetella pertussis is shown in SEQ ID No. 11, the fluorescent group labeled at the 5' end is FAM, and the quenching group labeled at the 3' end is BHQ2;
[0019] The sequence of the locked nucleic acid probe for Legionella pneumophila is shown in SEQ ID No. 12, the fluorescent group labeled at the 5' end is HEX, and the quenching group labeled at the 3' end is BHQ2;
[0020] The sequence of the locked nucleic acid probe for Chlamydia pneumoniae is shown in SEQ ID No. 13, the fluorescent group labeled at the 5' end is FAM, and the quenching group labeled at the 3' end is BHQ2;
[0021] The sequence of the locked nucleic acid probe of Mycoplasma pneumoniae is shown in SEQ ID No. 14, the fluorescent group labeled at the 5' end is HEX, and the quenching group labeled at the 3' end is BHQ2;
[0022] The sequence of the locked nucleic acid probe for Chlamydia trachomatis is shown in SEQ ID No. 15, the fluorescent group labeled at the 5' end is HEX, and the quenching group labeled at the 3' end is BHQ2.
[0023] Furthermore, the locked nucleic acid probes are divided into two groups, A and B: Group A includes locked nucleic acid probes for Bordetella pertussis and Legionella pneumophila; Group B includes locked nucleic acid probes for Chlamydia pneumoniae, Mycoplasma pneumoniae, and Chlamydia trachomatis; different locked nucleic acid probes in the same group have different fluorescent groups connected to their 5' ends.
[0024] The kit for detecting nucleic acid of atypical respiratory pathogens provided by the present invention is characterized in that it comprises an amplification primer pair and a locked nucleic acid probe for detecting nucleic acid of atypical respiratory pathogens.
[0025] Furthermore, it also includes a real-time fluorescence quantitative PCR reaction premix for PCR-probe method; the PCR reaction premix contains TaqDNA polymerase, Mg 2+ , dNTPs are reagents used for PCR amplification.
[0026] Furthermore, an internal standard control is included, and the internal standard control is used to detect an endogenous reference gene, an amplification primer pair and a locked nucleic acid probe encoding a human glyceraldehyde-3-phosphate dehydrogenase gene, the amplification primer pair sequence of the glyceraldehyde-3-phosphate dehydrogenase is shown in SEQ ID No. 16 and SEQ ID No. 17, and the locked nucleic acid probe sequence corresponding to the amplification primer pair is shown in SEQ ID No. 18; the fluorescent group at the 5' end of the locked nucleic acid probe is ROX, and the quenching group at the 3' end is BHQ2.
[0027] Furthermore, it also includes a negative control and a positive control; the negative control is deionized water; the positive control is a cloned plasmid including the respiratory atypical pathogen target gene and the internal reference gene fragment, wherein the nucleotide sequences of the respiratory atypical pathogen target gene and the internal reference gene fragment are shown in SEQ ID No. 19 to SEQ ID No. 24.
[0028] The use of the kit for detecting atypical respiratory pathogens provided by the present invention comprises the following steps:
[0029] S1: Extract DNA from the test specimen and positive control to obtain nucleic acid samples;
[0030] S2: preparing the amplification primer pair, locked nucleic acid probe, internal standard control and real-time fluorescence quantitative PCR reaction premix into reaction system A and reaction system B, i.e., tube A and tube B; tube A includes group A amplification primer pair, locked nucleic acid probe, internal standard control and real-time fluorescence quantitative PCR reaction premix; tube B includes group B amplification primer pair, locked nucleic acid probe, internal standard control and real-time fluorescence quantitative PCR reaction premix;
[0031] S3: Add the sample nucleic acid, positive control nucleic acid and negative control nucleic acid to the prepared tube A and tube B, respectively, place each PCR reaction tube in a fluorescent quantitative PCR instrument for amplification detection, obtain an amplification curve, and calculate the number of cycles experienced when the fluorescent signal in each reaction tube reaches the set threshold value, that is, the sample Ct value;
[0032] S4: Judge the validity of the experiment through the results of internal standard control, positive control, and negative control to ensure the accuracy of the results.
[0033] Furthermore, in step S3, the amplification conditions of the real-time fluorescence quantitative PCR reaction are as follows: step 1: pre-deformation: 95° C. for 2 min; step 2: amplification: 95° C. for 10 s, 57.5° C. for 30 s, and 40 cycles.
[0034] Based on the above technical solution, the embodiments of the present invention can at least produce the following technical effects:
[0035] First, the detection specificity is good. The amplification primer pairs and locked nucleic acid probes for detecting nucleic acids of five atypical respiratory pathogens provided by the present invention are designed based on the specific conservative nucleotide sequences of each pathogen, and after feedback and adjustment from preliminary experiments, the amplification primers and probes for various viruses are finally determined to ensure the specificity of the detection. In addition, the advantages of the locked nucleic acid probe also greatly improve the specificity of the detection.
[0036] Second, the detection sensitivity is high, the amplification efficiency is high, and the experimental repeatability is good. The formula of the components in the PCR reaction tube in the kit for detecting nucleic acids of five respiratory atypical pathogens provided by the present invention, especially the concentrations of the amplification primer pairs and the locked nucleic acid probes and the ratio between them, as well as the setting of the annealing temperature in the amplification conditions, are the results of multiple experimental optimizations, thereby ensuring that the detection has high sensitivity, high amplification efficiency and good repeatability.
[0037] Third, the test results are accurate. The present invention is designed for endogenous human internal reference genes, and the internal reference genes can be detected simultaneously with the nucleic acid test of the sample to be tested. The whole process from sample sampling to nucleic acid extraction and then to nucleic acid amplification is monitored by whether the internal reference gene test is normal, thereby avoiding false negative results; in addition, positive controls and negative controls are also provided in the kit, which are tested together with the sample to be tested in the same experiment, and the test results of the positive control and the negative control are used to monitor the process from sample addition to nucleic acid amplification, thereby avoiding false negative and false positive results.
[0038] Fourth, the kit can be applied to most real-time fluorescence quantitative PCR instruments. The kit provided by the present invention is used to detect nucleic acids of five atypical respiratory pathogens. The nucleic acid of the sample to be tested is added to tube A and tube B, and amplified simultaneously in two reaction tubes, thereby achieving the purpose of using a four-channel fluorescence quantitative PCR instrument for nucleic acid detection of five atypical respiratory pathogens.
[0039] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge scope of ordinary technicians in this field without departing from the purpose of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0041] Figure 1 is an amplification curve diagram of Bordetella pertussis and Legionella pneumophila of the present invention;
[0042] Figure 2 It is an amplification curve diagram of Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachomatis of the present invention;
[0043] Figure 3 This is an example diagram of the precision verification of Bordetella pertussis and Legionella pneumophila of the present invention;
[0044] Figure 4 This is an example diagram of the precision verification of Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachomatis of the present invention;
[0045] Figure 5 The standard curve of the fluorescence quantitative PCR of Bordetella pertussis of the present invention;
[0046] Figure 6 This is a standard curve diagram of the fluorescent quantitative PCR of Legionella pneumophila of the present invention;
[0047] Figure 7 It is a fluorescence quantitative PCR standard curve diagram of Chlamydia pneumoniae of the present invention;
[0048] Figure 8 This is a fluorescence quantitative PCR standard curve diagram of Mycoplasma pneumoniae of the present invention;
[0049] Fig. 9 The standard curve of the fluorescent quantitative PCR of Chlamydia trachomatis of the present invention;
[0050] In the attached figure: 1. Bordetella pertussis; 2. Legionella pneumophila; 3. Chlamydia pneumoniae; 4. Mycoplasma pneumoniae; 5. Chlamydia trachomatis. DETAILED DESCRIPTION
[0051] It should be understood that the specific embodiments described herein are only used to explain the present invention, and are not used to limit the present invention.
[0052] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. In addition, the technical solutions between the various embodiments can be combined with each other, but they must be based on the ability of ordinary technicians in this field to implement them. When the combination of technical solutions is contradictory or cannot be implemented, it should be considered that such a combination of technical solutions does not exist and is not within the scope of protection required by the present invention.
[0053] The objective of the present invention is achieved through the following technical solutions:
[0054] Example 1: Design of primers and locked nucleic acid probes
[0055] The design of primers and locked nucleic acid probes in the present invention focuses on the following two aspects:
[0056] First, guarantee of amplification specificity: According to literature reports, the specific and conservative nucleotide sequences of each pathogen were determined: the sequence of Bordetella pertussis was its BP485 gene sequence, the sequence of Legionella pneumophila was its mip gene sequence, the sequence of Chlamydia pneumoniae was its 16SrRNA gene sequence, the sequence of Mycoplasma pneumoniae was its P1 protein gene sequence, and the sequence of Chlamydia trachomatis was its endogenous plasmid gene sequence. The above sequences of the five atypical respiratory pathogens were downloaded from the GenBank database, and the specific conservative sequences of the same pathogens from different sources (strains) were imported into the DNAMAN9 software for nucleotide sequence consistency comparison, and the highly consistent nucleotide sequence regions were determined as the target gene sequences to be amplified for each subsequent pathogen.
[0057] Second: Guarantee of amplification efficiency: The target gene sequences of the five pathogens obtained above were imported into BeaconDesigner8 software for the design of multiplex fluorescence quantitative PCR amplification primers and locked nucleic acid probes, and the scheme with the highest score in the multiplex design was selected. The primer parameters were set as follows: length 18-25bp, Tm59℃±5℃, amplification product length 100-150bp; the probe parameters were set as follows: length 16-19bp, Tm=primer Tm+5℃~15℃, 4 locked nucleic acid labeled bases, 1 locked nucleic acid labeled base for every 3 bases, and 3 unlabeled locked nucleic acid bases at the 5' and 3' ends of the probe. The designed primers, locked nucleic acid probes, and amplification products were all verified by Blast.
[0058] Through the feedback of the test results, the design of primers and probes was adjusted, and finally the amplification primers and locked nucleic acid probes for detecting nucleic acids of five respiratory atypical pathogens with good specificity, less mutual interference and relatively ideal amplification efficiency were determined, as shown in Tables 2 and 3.
[0059] The amplification primers and locked nucleic acid probes for detecting nucleic acids of five atypical respiratory pathogens according to the embodiment of the present invention include primer pairs and locked nucleic acid probes designed for specific conserved sequences of Bordetella pertussis, Legionella pneumophila, Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachomatis, wherein the nucleotide sequence of the Bordetella pertussis amplification primer pair is shown in SEQ ID NO: 1 and SEQ ID NO: 2, and the nucleotide sequence of the Bordetella pertussis locked nucleic acid probe is shown in SEQ ID NO: 11; the nucleotide sequence of the Legionella pneumophila amplification primer pair is shown in SEQ ID NO: 3 and SEQ ID NO: 4, and the nucleotide sequence of the Legionella pneumophila locked nucleic acid probe is shown in SEQ ID NO: 12; the nucleotide sequence of the Chlamydia pneumoniae amplification primer pair is shown in SEQ ID NO: 5 and SEQ ID NO: 6, and the nucleotide sequence of the locked nucleic acid probe of Chlamydia pneumoniae is shown in SEQ ID NO: 13; the nucleotide sequence of the Mycoplasma pneumoniae amplification primer pair is shown in SEQ ID NO: 7 and SEQ ID NO: 8, and the nucleotide sequence of the locked nucleic acid probe of Mycoplasma pneumoniae is shown in SEQ ID NO: 14. NO:14; the nucleotide sequence of the Chlamydia trachomatis amplification primer pair is shown in SEQ ID NO:9 and SEQ ID NO:10, and the nucleotide sequence of the Chlamydia trachomatis locked nucleic acid probe is shown in SEQ ID NO:15.
[0060] The locked nucleic acid probe of Bordetella pertussis has a 5'-end fluorescent group of FAM and a 3'-end quenching group of BHQ2; the locked nucleic acid probe of Legionella pneumophila has a 5'-end fluorescent group of HEX and a 3'-end quenching group of BHQ2; the locked nucleic acid probe of Chlamydia pneumoniae has a 5'-end fluorescent group of FAM and a 3'-end quenching group of BHQ2; the locked nucleic acid probe of Mycoplasma pneumoniae has a 5'-end fluorescent group of HEX and a 3'-end quenching group of BHQ2; the locked nucleic acid probe of Chlamydia trachomatis has a 5'-end fluorescent group of CY5 and a 3'-end quenching group of BHQ2.
[0061] Table 2 Nucleotide sequences of amplification primers for atypical respiratory pathogens
[0062]
[0063] Table 3 Nucleotide sequences of locked nucleic acid probes for atypical respiratory pathogens
[0064]
[0065] *Capital position modified locked nucleic acid LNA
[0066] Example 2: Design of internal standard control amplification primers and locked nucleic acid probes
[0067] The present invention provides a kit for detecting nucleic acids of five atypical respiratory pathogens, including an internal standard control, i.e., an amplification primer pair and a locked nucleotide probe for detecting an endogenous internal reference gene GAPDH; the purpose of setting the internal standard control in the kit is to monitor the process of specimen sampling, nucleic acid extraction and amplification by detecting whether the endogenous internal reference gene is normal, so as to avoid false negative results. GAPDH is an enzyme in the classic glycolysis reaction. The enzyme is widely present in many organisms and is abundant in cells, accounting for 10% to 20% of the total protein. The GAPDH gene has a highly conserved sequence, and the protein expression level in the same cell or tissue is generally constant. Therefore, the gene has been widely used as an internal reference gene for quantitative PCR for a long time. The present invention designs amplification primers and locked nucleic acid probes based on the human GAPDH reference gene sequence. The amplification primer pair sequences of the internal reference gene are shown in SEQ ID No. 16 and SEQ ID No. 17, and the locked nucleic acid probe sequence corresponding to the amplification primer pair is shown in SEQ ID No. 18. The fluorescent group at the 5' end of the locked nucleic acid probe is ROX, and the quenching group at the 3' end is BHQ, see Table 4.
[0068] Table 4 Nucleotide sequences of amplification primers and locked nucleic acid probes of internal standard genes
[0069]
[0070] Example 3: Design of positive control
[0071] The present invention provides a kit for detecting diarrhea-causing viruses, including a positive control. The positive control is a cloned plasmid including the target genes and internal reference gene fragments of the five respiratory atypical pathogens, and its function is to prevent false negative results from occurring during the amplification process. The nucleotide sequences of the target genes and internal reference gene fragments of the five respiratory atypical pathogens contained in the positive control are shown in SEQ ID No. 19 to SEQ ID No. 24.
[0072] The nucleotide sequence of the target gene of Bordetella pertussis is shown in SEQ ID No. 19, and the specific sequence is: CATTTTCACTATGGGCTGTCGTGGCGGTCACGTCAAGCACAATCGCGCCATCGAGCCACTGTTTCTATTGATTGACAGGGCAATCCGGCAATAGCGCAGTCCGGCGTATCCTCCGCAGGGGCTCTGGGGAAAACACGCACAAAATTTCGCTGAACGAAGATGAGGCCCGGGTGGTGGCCGCCGCCTCCCGCTTCCACACG;
[0073] The nucleotide sequence of the target gene of Legionella pneumophila is shown in SEQ ID No. 20, and the specific sequence is: CCGATGCCACATCATTAGCTACAGACAAGGATAAGTTGTCTTATAGCATTGGTGCCGATTTGGGGAAGAATTTTAAAAATCAAGGCATAGATGTTAATCCGGAAGCAATGGCTAAAGGCATGCAAGACGCTATGAGTGGCGCTCAATTGGCTTTAACCGAACAGCAAATGAAAGACGTTCTTAACAAGTTTCAGAAAGAT;
[0074] The nucleotide sequence of the target gene of Chlamydia pneumoniae is shown in SEQ ID No. 21, and the specific sequence is: CCTTATCGTTAGTTGCCAGCACTTAGGGTGGGAACTCTAACGAGACTGCCTGGGTTAACCAGGAGGAAGGCGAGGATGACGTCAAGTCAGCATGGCCCTTATGTCCAGGGCGACACACGTGCTACAATGGTTAGTACAGAAGGTAGCAAGATCGTGAGATGGAGCAAATCCTAAAAGCTAGCCCCAGTTCGGATTGTAGT;
[0075] The nucleotide sequence of the target gene of Mycoplasma pneumoniae is shown in SEQ ID No. 22, and the specific sequence is: TCAGGCATGGTCAACAAACAAACTGACGGGTTAAAGAATCTACCCTTTAACAATAACCGCTGGTTTGAATATGTACCACGGATGGCAGTTGCTGGCGCTAAGTTCGTTGGTAGGGAACTCGTTTTAGCGGGTACCATTACCATGGGTGATACCGCTACCGTACCTCGCTTACTGTACGAT;
[0076] The nucleotide sequence of the target gene of Chlamydia trachomatis is shown in SEQ ID No. 23, and the specific sequence is: TAATCAGGTTGTTAACAGGATAGCACGCTCGGTATTTTTTTATATAAACATGAAAACTCGTTCCGAAATAGAAAATCGCATGCAAGATATCGAGTATGCGTTGTTAGGTAAAGCTCTGATATTTGAAGACTCTACTGAGTATATTCTGAGGCAGCTTGCTAATTATGAGTTTAAGTGTTC;
[0077] The nucleotide sequence of the internal standard gene is shown in SEQ ID No. 24, and the specific sequence is: TTTCCAGAATGTATCATTGGAATGATCCGGTATGGAGCCTTCTCACCTTGGCTTCTTAGTAATGTGCGTTTAAGGCCTCCATGTCTTCCATGGCCTTGTTTCTTTTTAATCAGAAGTAACTGTTTTCAGGCCTGCTCTGAATCTCCTTTTCTCCCTCCAGGCTATAATAGATGAATTTGAGCAGAAGCTT.
[0078] Example 4: Composition of a kit for detecting atypical respiratory pathogens
[0079] The main components of a kit for detecting atypical respiratory pathogens are shown in Table 5:
[0080] Table 5 Main components of the multiplex real-time fluorescence quantitative PCR kit for detecting atypical respiratory pathogens
[0081]
[0082] Example 5: Application of multiplex real-time fluorescence quantitative PCR kit for detecting atypical respiratory pathogens
[0083] S1: Nucleic acid extraction. Use a nucleic acid extraction kit to extract the DNA of the test sample and the positive control. For specific extraction steps, refer to the instructions of the extraction kit.
[0084] S2: Preparation of reaction system. The amplification primers and locked nucleic acid probes, internal standard controls and real-time fluorescence quantitative PCR reaction premixes in the kit of the present invention are prepared into two reaction systems, namely, reaction system A (tube A) and reaction system B (tube B); tube A includes amplification primers and locked nucleic acid probes, internal standard controls and real-time fluorescence quantitative PCR reaction premixes; tube B includes amplification primers and locked nucleic acid probes, internal standard controls and real-time fluorescence quantitative PCR reaction premixes.
[0085] Premix. Add 5 μl of the sample RNA, positive control, and negative control to tubes A and B, respectively.
[0086] The total reaction volume is 50 μl. See Table 6 and Table 7 for specific preparation schemes.
[0087] Table 6 A tube preparation scheme
[0088]
[0089] Table 7 Preparation of Group B
[0090]
[0091] S3: Settings for fluorescence quantitative PCR. The detection channels are set to FAM, HEX, CY5, and ROX. FAM corresponds to Bordetella pertussis in tube A and Chlamydia pneumoniae in tube B, HEX corresponds to Legionella pneumophila in tube A and Mycoplasma pneumoniae in tube B, CY5 corresponds to Chlamydia trachomatis in tube B, and ROX corresponds to the internal standard control of tubes A and B. Place each reaction tube in the PCR instrument, and set the PCR reaction conditions as shown in Table 8.
[0092] Table 8 Fluorescence quantitative PCR reaction conditions
[0093]
[0094] S4: Run the reaction program and view the results
[0095] S5: Result judgment
[0096] (1) Quality control
[0097] The following needs to be met simultaneously in the same experiment, otherwise the experiment is invalid.
[0098]
[0099] (2) Judgment of test sample results
[0100] Under the condition of quality control, the results of the samples to be tested are judged.
[0101]
[0102] Example 6: Precision verification of multiplex real-time fluorescence quantitative PCR method for detecting atypical respiratory pathogens
[0103] Precision verification should include repeatability tests and intermediate precision tests.
[0104] (1) Repeatability test
[0105] Dilute the positive controls of group A and group B by 10 5 Repeat the test 10 times. Figure 3 As shown. The results showed that after the nucleic acids of the two pathogens in group A were amplified by real-time fluorescence quantitative PCR, the coefficients of variation (CV) of the Ct values were 3.00% for Bordetella pertussis and 0.92% for Legionella pneumophila; after the nucleic acids of the three pathogens in group B were amplified by real-time fluorescence quantitative PCR, the coefficients of variation (CV) of the Ct values were 0.49% for Chlamydia pneumoniae, 0.52% for Mycoplasma pneumoniae, and 0.39% for Chlamydia trachomatis. The above results show that the CV values of the repeatability test of nucleic acid detection of the five respiratory pathogens are all less than 5%, and the repeatability is very good.
[0106] (2) Intermediate precision
[0107] The positive control of group A was 10 3 Times and 10 6 Dilute the sample twice to obtain two diluted samples (referred to as high concentration sample and low concentration sample). In addition, the positive control of group B is also diluted in the same way. Test one analysis batch every day, test two levels of samples in each batch, and repeat the test for each sample 5 times for 5 consecutive days. Figure 4The results showed that after the two pathogen nucleic acids in the high-concentration samples of group A were amplified by real-time fluorescence quantitative PCR, the coefficients of variation (CV) of the Ct values were 4.96% for Bordetella pertussis and 4.57% for Legionella pneumophila; after the two pathogen nucleic acids in the low-concentration samples of group A were amplified by real-time fluorescence quantitative PCR, the coefficients of variation (CV) of the Ct values were 4.55% for Bordetella pertussis and 3.57% for Legionella pneumophila; after the two viral nucleic acids in the high-concentration samples of group B were amplified by real-time fluorescence quantitative PCR, the coefficients of variation (CV) of the Ct values were 1.33% for Chlamydia pneumoniae, 0.65% for Mycoplasma pneumoniae, and 2.58% for Chlamydia trachomatis; after the three viral nucleic acids in the low-concentration samples of group B were amplified by real-time fluorescence quantitative PCR, the coefficients of variation (CV) of the Ct values were 0.39% for Chlamydia pneumoniae, 0.53% for Mycoplasma pneumoniae, and 2.70% for Chlamydia trachomatis. The above results show that the CV values of the intermediate tightness of the five viral nucleic acid tests are all less than 5%, and the precision is very good.
[0108] Example 6: Sensitivity test of multiplex real-time fluorescence quantitative PCR method for detecting atypical respiratory pathogens
[0109] The positive control was diluted 10 times in a row, and the detection kit of Example 5 was used to perform fluorescence quantitative PCR detection on the serially diluted nucleic acid samples. 14 Copies / ml~1.5×10 14 copies / ml) diluted 10 11 After 10 times the dilution, the Ct value was still less than 40, but after further dilution, there was no Ct value or the Ct was greater than 40. Therefore, the minimum detection limit of the five viruses in the kit of the present invention was 1.0×10 3 Copies / ml~1.5×10 3 copies / ml.
[0110] Example 7: Establishment of a standard curve for multiplex real-time fluorescence quantitative PCR for detecting atypical respiratory pathogens
[0111] The positive control was diluted to different concentrations and used as a template for PCR reaction. A standard curve was drawn with the logarithm of the dilution factor as the horizontal axis and the measured CT value as the vertical axis. Figures 5 to 9 It can be found that when the number of starting templates of the pathogen is approximately 10 4 ~10 11 When the R value of the standard curve of each virus is 2 It is greater than 0.99, with a small error, and the slope is close to the theoretical slope of -3.322, indicating high amplification efficiency.
[0112] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of the present invention to be protected is defined by the attached claims and their equivalents.
Claims
1. A kit for detecting nucleic acid of atypical respiratory pathogens, characterized in that: It includes an amplification primer pair for detecting nucleic acid of atypical respiratory pathogens and a locked nucleic acid probe for detecting nucleic acid of atypical respiratory pathogens; the amplification primer pair for detecting nucleic acid of atypical respiratory pathogens includes an amplification primer pair for Bordetella pertussis, Legionella pneumophila, Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachomatis; The sequences of the amplification primer pair for Bordetella pertussis are shown in SEQ ID No. 1 and SEQ ID No. 2; The sequences of the amplification primer pair for Legionella pneumophila are shown in SEQ ID No. 3 and SEQ ID No. 4; The sequences of the amplification primer pair for Chlamydia pneumoniae are shown in SEQ ID No. 5 and SEQ ID No. 6; The sequences of the amplification primer pair for Mycoplasma pneumoniae are shown in SEQ ID No. 7 and SEQ ID No. 8; The sequences of the amplification primer pair for Chlamydia trachomatis are shown in SEQ ID No. 9 and SEQ ID No. 10; The locked nucleic acid probes for detecting nucleic acids of atypical respiratory pathogens include locked nucleic acid probes for Bordetella pertussis, Legionella pneumophila, Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachomatis; The sequence of the locked nucleic acid probe for Bordetella pertussis is shown in SEQ ID No. 11, the fluorescent group labeled at the 5' end is FAM, and the quenching group labeled at the 3' end is BHQ2; The sequence of the locked nucleic acid probe for Legionella pneumophila is shown in SEQ ID No. 12, the fluorescent group labeled at the 5' end is HEX, and the quenching group labeled at the 3' end is BHQ2; The sequence of the locked nucleic acid probe for Chlamydia pneumoniae is shown in SEQ ID No. 13, the fluorescent group labeled at the 5' end is FAM, and the quenching group labeled at the 3' end is BHQ2; The sequence of the locked nucleic acid probe of Mycoplasma pneumoniae is shown in SEQ ID No. 14, the fluorescent group labeled at the 5' end is HEX, and the quenching group labeled at the 3' end is BHQ2; The sequence of the locked nucleic acid probe for Chlamydia trachomatis is shown in SEQ ID No. 15, the fluorescent group labeled at the 5' end is CY5, and the quenching group labeled at the 3' end is BHQ2; The amplification primer pairs are divided into two groups, A and B: Group A includes a primer pair for amplification of Bordetella pertussis and a primer pair for amplification of Legionella pneumophila; Group B includes a primer pair for amplification of Chlamydia pneumoniae, a primer pair for amplification of Mycoplasma pneumoniae, and a primer pair for amplification of Chlamydia trachomatis; The locked nucleic acid probes are divided into two groups, A and B: Group A includes locked nucleic acid probes for Bordetella pertussis and Legionella pneumophila; Group B includes locked nucleic acid probes for Chlamydia pneumoniae, Mycoplasma pneumoniae and Chlamydia trachomatis; different locked nucleic acid probes in the same group have different fluorescent groups connected to their 5' ends.
2. The kit for detecting nucleic acid of atypical respiratory pathogens according to claim 1, characterized in that: The invention also includes a real-time fluorescence quantitative PCR reaction premix for PCR-probe method; the PCR reaction premix contains TaqDNA polymerase, Mg 2+ , dNTPs are reagents used for PCR amplification.
3. The kit for detecting nucleic acid of atypical respiratory pathogens according to claim 1, characterized in that: It also includes an internal standard control, which is used to detect endogenous internal reference genes, an amplification primer pair and a locked nucleic acid probe encoding a human glyceraldehyde-3-phosphate dehydrogenase gene. The sequences of the amplification primer pair of glyceraldehyde-3-phosphate dehydrogenase are shown in SEQ ID No. 16 and SEQ ID No. 17, and the locked nucleic acid probe sequence corresponding to the amplification primer pair is shown in SEQ ID No. 18; the fluorescent group at the 5' end of the locked nucleic acid probe is ROX, and the quenching group at the 3' end is BHQ2.
4. The kit for detecting nucleic acid of atypical respiratory pathogens according to claim 1, characterized in that: It also includes a negative control and a positive control; the negative control is deionized water; the positive control is a cloned plasmid including the respiratory atypical pathogen target gene and the internal reference gene fragment, wherein the nucleotide sequences of the respiratory atypical pathogen target gene and the internal reference gene fragment are shown in SEQ ID No. 19 to SEQ ID No. 24.
